erdosteine
Sign in to saveErdosteine is a molecule with mucolytic activity. Structurally it is a thioether derivative with two thioether groups. These two functional organosulfur groups contained in the molecule are released following first-pass metabolism with the conversion of erdosteine into its pharmacologically active metabolite Met-I (N-thiodiglycolyl-homocysteine).
Research
225 papers- Erdosteine.Drugs · 1996
- Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.Respiratory research · 2019
- Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent.Drugs · 2020
- Erdosteine: antitussive and anti-inflammatory effects.Lung · 2008
- Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis.Pulmonary pharmacology & therapeutics · 2018
via PubMed
Wikidata facts
- Mass
- 249.013
Show 3 more facts
- chemical formula
- C₈H₁₁NO₄S₂
- canonical SMILES
- C1CSC(=O)C1NC(=O)CSCC(=O)O
- Commons category
- Erdosteine
via Wikidata · CC0
~10 min read
Article
14 sectionsContents
- Pharmacodynamics
- [[Antioxidant|Anti-oxidant]] and [[anti-inflammatory]] activity
- Antiadhesive activity
- [[Mucoactive agent|Mucolytic]] activity
- [[Chronic obstructive pulmonary disease|Chronic Obstructive Pulmonary Disease]]
- Other activities
- Pediatric population
- Pharmacokinetics
- Toxicity
- Clinical uses
- Safety profile
- Contraindications
- Interaction with other medicinal products
- References
Erdosteine is a molecule with mucolytic activity. Structurally it is a thioether derivative with two thioether groups. These two functional organosulfur groups contained in the molecule are released following first-pass metabolism with the conversion of erdosteine into its pharmacologically active metabolite Met-I (N-thiodiglycolyl-homocysteine).
The molecule has been discovered and developed in Italy by Edmond Pharma, today it is prescribed for chronic and acute respiratory disorders in more than 40 countries worldwide. The drug is sold under several commercial names (Esteclin, Erdomed, Erdos, Erdotin etc.), as hard capsules 300 mg, dispersible tablets 300 mg, granulates for oral suspension 225 mg and powder for oral suspension 175 mg/5ml.
Available in 11 languages
via Wikidata sitelinks · CC0